ProCE Banner Activity

Abstract: INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG).

PDF

Nick Pavlakis, MD discusses "INTEGRATE IIa: Randomised double-blind Phase III study of regorafenib versus placebo in refractory advanced Gastro-Oesophageal Cancer (AGOC)." in this virtual poster presentation.

Released: January 25, 2023

Expiration: January 24, 2024

Faculty

Nick Pavlakis

Nick Pavlakis, PhD, MBBS, FRACP

Medical Oncologist
Professor of Medicine
University of Sydney